J&J Reports 77% Response Rate in HPV-Unrelated Head and Neck Cancer Group

Your call?🐂 Bullish🐻 Bearish

77%

cancer response rate

The rate was 66% across all 29 evaluable participants. A randomized Phase 3 study will compare the regimen with pembrolizumab, platinum chemotherapy and 5-fluorouracil.